gdc
FDA NewsLeukemiaNewsworthy

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

December 2017 Vol 3 No 6

On August 17, 2017, the FDA approved the targeted therapy Besponsa (inotuzumab ozogamicin; from Pfizer) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

This approval was based on a clinical trial that showed complete response to therapy with Besponsa in more than one-third of patients who received the drug. Serious side effects include liver toxicity, such as veno-occlusive disease or sinusoidal obstruction syndrome, as well as increased risk of death if used after certain stem-cell transplants.

Recommended For You
Family MembersLeukemiaPediatric Cancer
Leukemia Is Shaping My Son’s Future
By Rachelle Donham
After his father’s diagnosis of acute lymphoblastic leukemia, 10-year-old Rhett is determined to become an oncologist to help other patients with cancer.
Leukemia
Chronic Lymphocytic Leukemia: The Silent Disease
By Lilly Ostrovsky
CLL is difficult to diagnose, because the symptoms only manifest in the later stages of the disease. As in all types of care, a late diagnosis often means worse prognosis.
CONQUER CamLeukemiaPatient Stories
CONQUER Cam: A Spotlight on Joyce Beecher
Joyce Beecher vividly recounts her cancer journey as a caregiver to her husband, Rich Beecher, who was diagnosed with chronic lymphocytic leukemia (CLL) in 2003. Listen to Joyce’s story as she describes their determination to find the best care and treatment for Rich, and encourages patients and caregivers to never give up.
CONQUER CamLeukemiaPatient Stories
CONQUER Cam: A Spotlight on Rich Beecher
Diagnosed in 2003, Rich Beecher has been living with chronic lymphocytic leukemia (CLL) for 15 years. Rich describes his cancer journey – from “Why me?” to focusing on the positive things in his life, including immersing himself more in photography.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country